ESMO Virtual Congress 2020: Pembrolizumab Combined with Chemotherapy vs Chemotherapy Alone as First-Line Therapy for Advanced Urothelial Carcinoma: KEYNOTE-361

(UroToday.com) At this year’s European Society for Medical Oncology (ESMO) 2020 Virtual Congress, Dr. Ajjai Alva presented the final results from KEYNOTE-361, a trial of pembrolizumab +/- chemotherapy in advanced urothelial carcinoma.